Skip to main content
Article thumbnail
Location of Repository

Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review

By Andrea Rubbert-Roth and Axel Finckh

Abstract

Conventional disease-modifying antirheumatic drugs such as methotrexate are the mainstay of treatment for rheumatoid arthritis. More recently, biologic agents such as etanercept, infliximab and adalimumab, which act by inhibiting tumour necrosis factor (TNF), have become available. TNF inhibitors have proved to be very effective in patients not responding to conventional disease-modifying antirheumatic drugs. However, about 20% to 40% of patients treated with a TNF inhibitor fail to achieve a 20% improvement in American College of Rheumatology criteria, and more lose response over time (secondary failure or acquired therapeutic resistance) or experience adverse events following treatment with a TNF inhibitor. In this group of patients, therapeutic options were limited until recently and an established treatment approach was to switch from one TNF inhibitor to another. In recent years, therapeutic options in these patients have increased with the introduction of biologic agents with novel mechanisms of action, such as rituximab and abatacept. This review outlines the current evidence in support of the available treatment strategies in patients with an inadequate response or intolerance to an initial TNF inhibitor

Topics: Review
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2669237
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2005). Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
    2. (2004). Abramson SB: Overview of benefit/risk of biological agents. Clin Exp Rheumatol
    3. (2006). Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA
    4. (2008). Bendtzen K: Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis
    5. (2007). Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum
    6. (2002). Cerhan JR: Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women’s Health Study. Ann Rheum Dis
    7. (2003). Chartash EK: Adalimumab, a fully human anti-tumor necrosis factor α α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum
    8. Continued inhibition of structural damage in rheumatoid arthritis patients treated with rituximab at 2 years: Reflex study [abstract]. Ann Rheum Dis 2008, 67(suppl II):189.
    9. (2005). DE: The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum
    10. der Heijde D: Radiographic inhibition of progression of structural damage: results from the RAPID 2 trial. Ann Rheum Dis 2008, 67(suppl II):321.
    11. (2004). Eickenhorst T: Switching anti-TNF therapy: real world outcome of patients with rheumatoid arthritis who failed either infliximab or etanercept of treatment and switched to another TNF inhibitor [abstract]. Arthritis Rheum
    12. (2003). EL: Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum
    13. (2004). Erkan D: Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed? Ann Rheum Dis
    14. (2008). Evidence for differential acquired drug resistance to anti-TNF agents in rheumatoid arthritis. Ann Rheum Dis
    15. (2008). F: Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to antitumor necrosis factor therapy. Arthritis Rheum
    16. F: Observed and expected malignancies in the abatacept clinical development program: an epidemiological assessment [abstract]. Ann Rheum Dis 2006, 65(suppl II):
    17. (2007). Failure of adalimumab in patients with rheumatoid arthritis [abstract]. Arthritis Rheum
    18. (2000). Finck BK: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.
    19. (2007). Furstenberg CT: Outcomes after switching from one antitumor necrosis factor α α agent to a second anti-tumor necrosis factor α α agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum
    20. (2007). GR: Research in Active Rheumatoid Arthritis (ReAct) Study Group: effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford)
    21. (2007). Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease.
    22. (2007). Immunoglobulin levels and infection rates in patients with rheumatoid arthritis treated with repeated courses of rituximab [abstract]. Arthritis Rheum
    23. (1999). Infliximab (chimeric anti-tumour necrosis factor α α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet
    24. Klareskog L: Experience with rituximab in the treatment of rheumatoid arthritis (RA): results from the Sture Registry [abstract]. Ann Rheum Dis 2008, 67(suppl II):340.
    25. (2007). Klareskog L: Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis
    26. (1999). Loew-Friedrich I: Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med
    27. (2007). Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders. Rheumatology (Oxford)
    28. (2004). Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum
    29. (2007). Magrini F: Extended follow-up of the long-term safety of rituximab in rheumatoid arthritis [abstract]. Arthritis Rheum
    30. (2006). Marsal S: EULAR response in clinical practice in RA patients treated with one, two or three antiTNF alpha agents: results of an observational, prospective, cohort study in Spain [abstract]. Arthritis Rheum
    31. (2008). MM: Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum
    32. Orencia® [abatacept] prescribing information.
    33. (2006). Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum
    34. (2007). RF: Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue. Ann Rheum Dis
    35. (2009). Rituximab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis
    36. (2008). Rituximab may be more effective than switching to an alternative TNF inhibitor in rheumatoid arthritis patients who have failed other TNF inhibitors. Rheumatology (Oxford)
    37. RM: Early inhibition of progression of structural damage in certolizumab pegol-treated patients: 16-week efficacy results from RAPID. Ann Rheum Dis 2008, 67(suppl II):51.
    38. (2000). RN: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
    39. (2007). S: B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum
    40. Safa-Leathers S: Efficacy of rituximab in active RA patients with an inadequate response to one or more TNF inhibitors. Ann Rheum Dis 2006, 65(suppl II):326.
    41. (2007). Safa-Leathers S: Repeat treatment with rituximab in active RA patients: long-term efficacy in patients with one versus two or more prior TNF inhibitors. Ann Rheum Dis
    42. Safety of TNF inhibitors and non-biologic DMARDs in rheumatoid arthritis patients previously treated with rituximab [abstract].
    43. (2006). Sasso EH: Adalimumab plus methotrexate results in less frequent and less severe radiographic progression than methotrexate alone at all levels of clinical response in early rheumatoid arthritis [abstract]. Ann Rheum Dis
    44. (2005). SB: Drug survival time on anti-TNF agents: does prior anti-TNF use influence RA outcomes? [Abstract]. Arthritis Rheum
    45. Sokka T: Benefit/risk of therapies for rheumatoid arthritis: underestimation of the ‘side effects’ or risks of RA leads to underestimation of the benefit/risk of therapies. Clin Exp Rheumatol 2004, 22(suppl 35):S2-S11.
    46. Summary of product characteristics: MabThera 100mg and 500mg concentrate for solution for infusion.
    47. Switching between antiTNF therapies does not affect level of adherence to therapy in rheumatoid arthritis but response rates seem to decline. [abstract]. Ann Rheum Dis 2006, 65(suppl II):327.
    48. (2006). Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther
    49. (2006). Symmons D: The incidence of serious infections is not increased in patients with rheumatoid arthritis treated with anti-TNF drugs compared to those treated with traditional DMARDs: results from a national prospective study [abstract]. Arthritis Rheum
    50. (2008). Symmons DPM: Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first antiTNF drug. Rheumatology (Oxford)
    51. (2008). Tak PP: Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther
    52. (2006). The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum
    53. (2004). Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: doubleblind randomised controlled trial. Lancet
    54. (2007). TL: Effectiveness of a switch to a second anti-TNF-α α in primary nonresponders, secondary nonresponders and failure due to adverse events [abstract]. Arthritis Rheum
    55. Tocilizumab (TCZ) significantly improves disease outcomes in patients with rheumatoid arthritis whose anti-TNF therapy failed: the RADIATE study [abstract]. Ann Rheum Dis 2008, 67(suppl II):127.
    56. (2008). Treatment response to a second or third TNFinhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology
    57. (2007). Troum O: Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: The OPPOSITE study. Ann Rheum Dis
    58. (2006). Use of tumor necrosis factor inhibitors in rheumatoid arthritis: a national survey of practicing United States rheumatologists. Joint Bone Spine
    59. (2002). Wegener’s Granulomatosis Etanercept Trial (WGET) Research Group: Etanercept plus standard therapy for Wegener’s granulomatosis.
    60. (2001). Weinblatt ME: Rheumatoid arthritis. Lancet
    61. (2007). Weinblatt ME: Updated consensus statement on biological agents for the treatment of rheumatic diseases,
    62. (2006). Westhovens R: Effects of abatacept in patients with methotrexateresistant active rheumatoid arthritis: a randomized trial. Ann Intern Med
    63. Which subgroup of rheumatoid arthritis patients benefit most from switching to rituximab versus alternative anti-TNF agents after previous failure to anti-TNF agents? [Abstract]. Ann Rheum Dis 2008, 67(suppl II):127.
    64. (2005). Zink A: Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.